KPV.

KPV is a research compound in the thymic & immune-modulating peptides.

Modulating immune-cell activity and inflammation.

It draws interest for thymic & immune-modulating peptides.

F-tier evidence: human evidence is limited; most support is preclinical.

What it is

KPV is a synthetic tripeptide composed of L-lysine, L-proline, and L-valine (Lys-Pro-Val), corresponding to the C-terminal residues 11-13 of alpha-melanocyte-stimulating hormone (alpha-MSH). It is the smallest fragment of alpha-MSH that retains the parent hormone's anti-inflammatory activity, and it is studied as a melanocortin-derived anti-inflammatory agent that lacks the pigmentary (melanogenic) action of the full hormone. It is a research compound, not an approved drug.

How it works

KPV's anti-inflammatory action appears to be largely receptor-independent: rather than signaling primarily through classical melanocortin receptors, it is taken up into intestinal epithelial and immune cells by the proton-coupled di/tripeptide transporter PepT1 (SLC15A1), which is normally restricted to the small intestine but is induced in the colon during inflammation. Once intracellular, KPV dampens canonical pro-inflammatory signaling, notably inhibiting NF-kB and MAP-kinase pathway activation and reducing secretion of pro-inflammatory cytokines. Work dissecting alpha-MSH fragments also implicates antagonism of IL-1beta-driven inflammatory functions as a contributor to its effect. This combination of mechanisms is the basis for its preclinical study in mucosal inflammation.

What the evidence shows

The evidence base for KPV is preclinical (cell culture and rodent models); there are no completed human clinical trials demonstrating efficacy or safety. Dalmasso and colleagues (Gastroenterology, 2008) showed that nanomolar KPV inhibited NF-kB and MAP-kinase activation in human intestinal epithelial (Caco2-BBE, HT29-Cl.19A) and Jurkat T cells via PepT1, and that oral KPV reduced DSS- and TNBS-induced colitis in mice. Kannengiesser et al. (Inflammatory Bowel Diseases, 2008) reported that KPV attenuated disease in DSS and CD45RB-transfer murine colitis models, with effects that did not require functional MC1R, supporting a non-melanocortin-receptor mechanism. Earlier mechanistic dissection by Getting, Schioth, and Perretti (J Pharmacol Exp Ther, 2003) compared core and C-terminal (KPV) alpha-MSH peptides and characterized their anti-inflammatory pharmacology. The broader pharmacology is summarized in a review by Brzoska et al. (Endocrine Reviews, 2008); the gap to human disease remains unbridged.

Safety considerations

Documented safety data come almost entirely from cell and rodent studies, where KPV has generally been reported as well tolerated at the doses tested; there is no established human safety profile, no characterized adverse-event spectrum in people, and no pharmacovigilance data. Long-term effects, immunogenicity, effects in pregnancy, and drug interactions are unknown. Because PepT1 expression and KPV uptake are upregulated specifically in inflamed tissue, the cellular pharmacology may differ between healthy and diseased states, which is not characterized in humans. Material sold for research or compounded use is not subject to pharmaceutical-grade quality control, introducing additional purity and identity risks.

Regulatory status

KPV is not approved by the FDA (or other major regulators) for any indication and has no marketed drug product; it is an investigational/research-use compound. It is not a recognized dietary supplement ingredient, and any human use occurs outside of established regulatory approval.

1. [1]PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation — Gastroenterology, 2008, Dalmasso G et al., PMID 18061177
2. [2]Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease — Inflammatory Bowel Diseases, 2008, Kannengiesser K et al., PMID 18092346
3. [3]Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides — Journal of Pharmacology and Experimental Therapeutics, 2003, Getting SJ, Schioth HB, Perretti M, PMID 12750433
4. [4]Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo — Endocrine Reviews, 2008, Brzoska T et al., PMID 18612139

• Not FDA-approved; research-only.
• Human evidence is limited; benefits are largely preclinical.

Stack fit

Why not D: held back by human evidence, safety clarity, regulatory clarity, practical relevance.

What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.

What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.

• KPV is not FDA-approved for human use; it is discussed in a research context.
• It belongs to the Thymic & immune-modulating peptides class.
• Its principal mechanism is characterized in the literature.

• Whether observed effects reliably translate to humans at large.
• Long-term safety in healthy users, and full drug-interaction risk.
• Optimal studied parameters outside any approved indication.
• Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
• Quality and purity of material from non-pharmaceutical sources.

1. What it is
2. The Thymic & immune modulation mechanism
3. The preclinical evidence lane
4. Why Preliminary, and not higher or lower
5. Proven lane vs speculative lane
6. What people report
7. Regulatory status
8. What changed recently